Evekeo

Draft medication scaffold. Needs source pass before publish.

Sections

1. The basics
2. Side effects that actually matter
3. When Evekeo fits and when it doesn’t
4. Racemic amphetamine: what the 50/50 ratio actually means
5. The obesity approval: historical context
6. Dosing and scheduling
7. Evekeo compared to Adderall and other amphetamine options
8. Narcolepsy: the other listed indication
9. Managing a stimulant holiday
10. Who prescribes Evekeo and why
11. What to know before stopping or switching
12. Sources

Evekeo is plain amphetamine sulfate, which makes it feel almost old-school compared with the newer stimulant products built around complicated release systems and marketing language. Sometimes that simplicity is a strength. Sometimes it just means you’ve got less forgiveness on timing.

The basics

Evekeo is an immediate-release amphetamine sulfate tablet. The label includes ADHD, narcolepsy, and short-term use for exogenous obesity, though in everyday psychiatry the ADHD use is what matters most.1 Dosing for ADHD is usually split across the day rather than handled as a once-daily capsule, which means the clinician and the patient have more control over when it starts and when it stops. That can be very useful when the main problem is calibration rather than duration.

Side effects that actually matter

The familiar stimulant risks all apply: appetite loss, insomnia, increased heart rate or blood pressure, anxiety, irritability, misuse risk, and rare psychiatric destabilization in vulnerable patients.1 With an immediate-release product, rebound irritability or a sharp drop in effect can matter more because the edges are easier to feel. Since Evekeo contains both d-amphetamine and l-amphetamine, some patients also describe a more physical or activating feel than they get from some other amphetamine products, though that isn’t a clean rule and individual response still dominates.

When Evekeo fits and when it doesn’t

Evekeo fits when the goal is flexible, titrated coverage with a clear on and off pattern. New stimulant start where you want small dose increments and quick feedback, someone who only needs coverage for part of the day, or a situation where the prescriber is still working out whether amphetamine is better than methylphenidate for this particular patient. Poor adherence, high misuse risk, and patients who clearly need smoother all-day coverage all work against immediate-release products across the board, not just for Evekeo.

Racemic amphetamine: what the 50/50 ratio actually means

Amphetamine comes in two mirror-image forms: dextroamphetamine (d-isomer) and levoamphetamine (l-isomer). The two isomers have different potencies and slightly different side effect profiles. Dextroamphetamine is the more potent central nervous system stimulant and is primarily responsible for the therapeutic effect on attention and impulse control. Levoamphetamine has more peripheral effects, meaning more cardiovascular activation relative to central effect.

Adderall is mixed amphetamine salts at a roughly 75/25 d-to-l ratio. Vyvanse delivers only dextroamphetamine through its prodrug mechanism. Evekeo is the opposite end of that spectrum: it’s a 50/50 mix, meaning it has more l-isomer per dose than any other amphetamine product in common use. That’s the pharmacological distinction that makes Evekeo different, and it’s also why some patients describe it as more physically activating or more cardiovascularly stimulating compared to Adderall or Vyvanse.

Whether the higher l-isomer proportion is a feature or a drawback depends entirely on the patient. For most people, it’s not a clinically meaningful difference from Adderall. For some, especially those who find Adderall too cardiovascularly activating, adding more l-isomer is the wrong direction. There’s no population-level evidence showing Evekeo is superior to other amphetamine products for ADHD; the difference is pharmacological and individual, not universal.

The obesity approval: historical context

Evekeo’s labeling includes short-term treatment of exogenous obesity, which is a holdover from the era when amphetamines were prescribed as appetite suppressants. This indication is rarely used in contemporary psychiatry. Weight loss via stimulant is real but short-lived as tolerance to appetite effects develops, the regain pattern on discontinuation is predictable, and there are safer options for patients where appetite suppression is the goal.

The obesity indication on the label sometimes confuses patients who see it listed. It’s worth addressing directly: the reason Evekeo gets prescribed for ADHD is not because of the obesity indication, and patients shouldn’t read the appetite suppression side effect as an intended therapeutic benefit.

Dosing and scheduling

ADHD dosing for adults typically starts at 5 mg once or twice daily and is adjusted upward based on response, with most adults landing somewhere between 5 and 40 mg per day divided across two or sometimes three doses. Children 3 to 5 start at 2.5 mg once daily. Children 6 and older typically start at 5 mg once daily, with titration in 5 mg increments.

The last dose of the day timing matters more with immediate-release products than with extended release. Taking a dose too late creates predictable insomnia. A reasonable rule of thumb for most patients is to avoid dosing after 3 or 4 pm, with earlier cutoffs for anyone already struggling with sleep onset. Some patients do better with two doses (morning and early afternoon) than with three, because the third dose often helps with afternoon focus but costs them an hour of sleep time.

Evekeo compared to Adderall and other amphetamine options

In practice, Evekeo and generic immediate-release amphetamine salts (generic Adderall) occupy similar niches. The meaningful difference is the isomer ratio. For a patient who has used generic immediate-release amphetamine salts before, the Evekeo experience may feel more physically activating due to the higher l-isomer content. For a patient starting amphetamine for the first time, the difference is unlikely to be noticeable at standard starting doses.

Dexedrine is the only other immediate-release amphetamine that offers a useful comparison: pure dextroamphetamine, the opposite of Evekeo’s more balanced ratio. If a patient has tried Dexedrine and found it effective but too cardiovascularly activating, that’s actually an argument against adding more l-isomer via Evekeo, not for it. If they found Adderall IR too activating and want to try something with less central effect and more peripheral activation, that’s also Evekeo going the wrong direction.

The cases where Evekeo specifically adds value tend to be narrow: branded coverage when insurance makes generic immediate-release amphetamine salts difficult to access, or specific situations where the racemic formulation is clinically preferred for a documented reason. For most patients, generic immediate-release amphetamine salts do the same job at lower cost.

Narcolepsy: the other listed indication

Evekeo is labeled for narcolepsy in addition to ADHD. Narcolepsy is characterized by excessive daytime sleepiness, often with cataplexy (sudden muscle weakness triggered by emotion), and is caused by loss of hypocretin neurons in the hypothalamus. Amphetamines address the sleepiness side by increasing norepinephrine and dopamine in the arousal circuits of the brain.

Modafinil and armodafinil are the more common wakefulness-promoting agents for narcolepsy today, and sodium oxybate is used for patients with cataplexy. Amphetamines remain a legitimate option when those fail or aren’t tolerated, and their efficacy for promoting wakefulness is well established. The cardiovascular effects and misuse potential that are concerns in ADHD remain concerns in narcolepsy, but the risk-benefit calculation looks different when the alternative is dangerous levels of daytime sleepiness.

Managing a stimulant holiday

Some patients and families want periods off stimulants, especially during school breaks or summers. Immediate-release products like Evekeo are easy to stop and restart compared to extended release products that take longer to clear. A weekend off is possible. A summer off is possible. The conversation to have before doing this is what to expect: ADHD symptoms return to baseline, there may be a few days of relative fatigue or decreased motivation as the system readjusts, and any weight or growth benefit from taking a break will depend on how much appetite suppression was affecting the child during treatment.

Not every patient benefits from drug holidays. For adults who need stimulant coverage for work or daily function, a planned break may create more problems than it solves. For kids who can manage summer schedule without consistent medication, the break can give the system a rest. Neither approach is universally right.

Who prescribes Evekeo and why

In current practice, Evekeo gets prescribed most often in situations where insurance coverage or formulary constraints make it the covered amphetamine option, where a prescriber wants the flexibility of racemic amphetamine at a specific ratio, or where prior authorization requirements for other amphetamine products have created access issues. It’s not a first-choice stimulant for most prescribers, but it’s not a fringe product either, and the clinical performance is what you’d expect from an immediate-release amphetamine at standard doses.

What to know before stopping or switching

You don’t taper Evekeo in the formal withdrawal sense, but you do want to account for the fact that stopping it can uncover fatigue, lower motivation, or a more obvious ADHD baseline. If you’re switching from Evekeo to a longer-acting stimulant, the main question isn’t whether they’re both amphetamines. It’s how much duration you’re adding and whether you’re trading flexibility for smoother coverage. Because the medicine is short acting, schedule details matter more than people sometimes realize.1

Sources

1. DailyMed. Evekeo prescribing information. Updated November 2025. Accessed June 6, 2026. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=f469fb38-0380-4621-9db3-a4f429126156

2. Wigal SB, Childress AC, Belden HW, Berry SA. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study. J Child Adolesc Psychopharmacol. 2015;25(5):402-414. PMID 25692608. https://pubmed.ncbi.nlm.nih.gov/25692608/

3. Coghill D. Racemic amphetamine sulfate (Evekeo) for ADHD. Drugs Today (Barc). 2015;51(9):529-539. PMID 26393827. https://pubmed.ncbi.nlm.nih.gov/26393827/